A Phase 3 interventional study of Epiduo/Tactuo and vehicle gel in Acne, sponsored by Galderma R&D. Completed at 26 sites in Canada. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.
Among the 12 studies testing doxycycline in Acne Vulgaris, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 6th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Sites in Bangladesh
Ages 18+
By country, each count listing its studies:
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 6
First in 2005; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 266 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 47 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 20th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2011, is one of 20 in phase 3, and was the 22nd registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
2 of the studies testing doxycycline in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07544251Integrative Skin Science and ResearchComparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne. | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Epiduo/Tactuo · Drug: doxycycline 200mg
Other: vehicle gel · Drug: Isotretinoin
topical to the face, once daily in the evening
topical to the face, once daily in the evening
oral, 2 capsules once daily in the morning with aglass of water and with food
oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements
Overall success is reached when the 2 following criteria are fulfilled : 1. Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment 2. Safe treatment: Absence of any listed safety issues
Time frame: 20 weeks
| Milestone | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel |
|---|---|---|
| Started | 133 | 133 |
| Completed | 105 | 116 |
| Not completed | 28 | 17 |
Overall success is reached when the 2 following criteria are fulfilled : 1. Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment 2. Safe treatment: Absence of any listed safety issues
| count of participants | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel |
|---|---|---|
| The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements | 85 | 73 |
Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epiduo/Tactuo + Doxycycline 200mg | — | 0/133 (0%) | 25/133 (18.8%) |
| Isotretinoin + Vehicle Gel | — | 1/133 (0.8%) | 66/133 (49.6%) |
| Event | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel |
|---|---|---|
| Stevens-Johnson syndromeSkin and subcutaneous tissue disorders | 0/133 | 1/133 |
| Event | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel |
|---|---|---|
| lip dryGastrointestinal disorders | 9/133 | 66/133 |
| dry skinSkin and subcutaneous tissue disorders | 25/133 | 43/133 |
| cheilitisGastrointestinal disorders | 2/133 | 32/133 |
| naospharyngitisInfections and infestations | 15/133 | 14/133 |
| skin irritationSkin and subcutaneous tissue disorders | 14/133 | 7/133 |
| nauseaGastrointestinal disorders | 14/133 | 5/133 |
| UPTRI (Upper Tract Respiratory Infection)Infections and infestations | 9/133 | 13/133 |
| headacheNervous system disorders | 12/133 | 11/133 |
| vomitingGastrointestinal disorders | 12/133 | 2/133 |
| Age, Continuous(years) | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel | Total |
|---|---|---|---|
| Mean | 19.5 ± 5.0 | 19.3 ± 4.5 | 19.4 ± 4.8 |
| Sex: Female, Male(Participants) | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel | Total |
|---|---|---|---|
| Female | 18 | 21 | 39 |
| Male | 115 | 112 | 227 |
| Region of Enrollment(count of participants) | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel | Total |
|---|---|---|---|
| Canada | 133 | 133 | 266 |
| IGA(count of participants) | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel | Total |
|---|---|---|---|
| 4 | 118 | 115 | 233 |
| 5 | 15 | 18 | 33 |
| nodule counts(nodules) | Epiduo/Tactuo + Doxycycline 200mg | Isotretinoin + Vehicle Gel | Total |
|---|---|---|---|
| Mean | 8.0 ± 3.6 | 7.6 ± 2.5 | 7.8 ± 3.1 |
The record gives a start of Nov 2011, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline